-
Merck Sharp & Dohme Corp. v. Xellia Pharmaceuticals ApS DC CAFC
- 1:14-cv-00199
- D. Del.
- Filed: 02/14/2014
- Closed: 07/09/2015
- Latest Docket Entry: 11/14/2017
- Judge: Richard G. Andrews
- PACER
1
Plaintiff
2
Defendants
1
Accused
Product
1
Patent-in-Suit
511
Days in
Litigation
-
Merck Sharp & Dohme Corp. v. Xellia Pharmaceuticals ApS DC CAFC
- 1:14-cv-00199
- D. Del.
- Filed: 02/14/2014
- Closed: 07/09/2015
- Latest Docket Entry: 11/14/2017
- Judge: Richard G. Andrews
- PACER
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 121 |
-
Infringement
Xellia Pharmaceuticals APS
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 50 mg, 70 mg caspofungin acetate injectable IVcaspofungin acetate injectable, IV (infusion) | US 5,952,300 A |
1
|
Infringement
Entry 109Entry 114 |
Xellia Pharmaceuticals Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 50 mg, 70 mg caspofungin acetate injectable IVcaspofungin acetate injectable, IV (infusion) | US 5,952,300 A |
1
|
Infringement
Entry 109Entry 114 |